Federico is a computational biologist with deep expertise in mathematical modelling and molecular biophysics. He holds a PhD in Molecular and Computational Oncology from the University of Oxford and has previously worked at the World Health Organization assessing cancer prevention strategies.

Andrea is an experienced machine learning scientist. He holds a PhD in Bio-Inspired Computation and has several years of experience building AI. He previously led the ML team at Portent.io (acquired by Yougov) and has worked at the European Space Agency, Honda Research Institute and Vodafone.

Sebastian was the scientific mastermind behind the T cell engager programmes at Immatics (NASDAQ: IMTX). He spearheaded IMA401 and IMA402 from discovery all the way to first-in-human clinical trials, and unlocked the $150M upfront deal with BMS. Sebastian brings key scientific and commercial experience to help us develop and advance our assets towards the clinic.

Muhammad holds a PhD in Mathematical Biology and Biophysical Chemistry from the University of Warwick. Over the last decade, he has worked on a broad range of protein engineering and structural biology projects at the interface of Physics, Chemistry and Biology. Prior to joining Exogene, he had been working on developing novel methods for the study and diagnostics of the SARS-CoV-2 virus.

Giovanni is a seasoned computational biologist with 6+ years experience in molecular dynamics and machine learning applied to TCR discovery and engineering from his time at Ardigen. Giovanni holds a PhD in Computer Science from the Polish Academy of Sciences.

Jan-Gert is a protein biochemist with a PhD in Biology from the University of York. He previously worked at Memorial Sloan Kettering Cancer Center (MSKCC) developing in vitro assays to study how the DNA replication machinery deals with obstacles such as DNA damage and protein roadblocks to maintain genome integrity.

Alex is an experienced machine learning expert specialising in AI for biomedical research. At Ardigen, he served as a SCRUM master and developed models to predict peptide-HLA and TCR-pHLA binding. During his PhD at the Warsaw University of Technology, he focused on in-silico modelling of antigen recognition using machine learning.

James is a project and operations manager with a strong background in tech start-ups. He previously helped scale high-throughput PCR testing operations at Oncologica and led projects to commercialise novel biomaterials at Xampla. James holds an MSci in Natural Sciences from the University of Bath.

Ryan is an experienced machine learning scientist with a PhD in Chemistry from Cornell University. He joined Exogene from the machine learning group at Bayer and his recent work there was published at ICML. He previously worked at Intel, and in his spare time he participates in machine learning competitions.

Foram is a cell biologist and immunologist with over five years of experience in oncology and immunotherapy. She earned her PhD from the University of Plymouth and has since contributed to cutting-edge research at Scancell, where she played a pivotal role in advancing bispecific T-cell engager programs through both in vitro and in vivo preclinical development.

Jose Enrique holds a PhD in Pharmacology from the University of Cambridge. His doctoral research focused on the selection and characterisation of functional antibodies or nanobodies targeting challenging neuronal ion channels. Through his prior work, he has acquired significant experience in molecular biology, protein engineering, structural biology, and yeast display technology.

Anthony is a molecular cell biologist with a PhD in Cellular Microbiology from the University of Cambridge. Whilst working in Academia he specialised in Host-Pathogen Interactions with a decade of research dedicated to the molecular mechanisms of bacterial entry. He recently transitioned into industry using his skills in cell engineering and assay development to characterise novel T-cell engagers.

Ricardo is a world expert in wet-lab methods for high-throughput screening of TCR-target pairs. He is a Principal Investigator at the University of Oxford and he has published in high-profile journals such as Nature Immunology, Cell and PNAS.

Alasdair has extensive experience negotiating and managing AI-driven co-development partnerships in the biopharmaceutical industry. He is a Founding Partner at Selvedge Venture and former director of deep-tech venture investments at Leaps by Bayer.

Livio is the co-founder of Vaxess Technologies, where he has pioneered a novel vaccine patch, raised over $80 million in funding, and collaborated with AstraZeneca on mRNA vaccine technologies. Before Vaxess, he worked at the United Nations, implementing silk production programs in Asia. Livio was named in the 2014 Forbes 30 under 30 list and holds a Masters in Public Policy from Harvard Kennedy School.

Prof. Paul Nathan is a leading medical oncologist at Mount Vernon Cancer Centre (UK) and a key opinion leader in kidney cancer. He played a pivotal role in leading the Phase 3 trial of Kimmtrak, a TCR-based bispecific T-cell engager therapy for uveal melanoma, which ultimately secured FDA approval.